Grants Search Results

This institution is a member of a research consortium which is being funded by St. Baldrick's: Preventing Heart Injury During Cancer Treatment. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Preventing Heart Injury During Cancer Treatment. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Preventing Heart Injury During Cancer Treatment. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Preventing Heart Injury During Cancer Treatment. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Preventing Heart Injury During Cancer Treatment. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

This institution is a member of a research consortium which is being funded by St. Baldrick's: Preventing Heart Injury During Cancer Treatment. For a description of this project, see the consortium grant made to the lead institution: Fred Hutchinson Cancer Research Center, Seattle, WA.

Based on progress to date, Dr. Allen-Rhoades was awarded a new grant in 2014 to fund an optional third year of this fellowship. Osteosarcoma is a bone cancer that affects children, adolescents and young adults. Patients have better survival if the cancer has not spread to other parts of the body. This project aims to develop a blood test that can detect the cancer and determine if it has spread to other areas. This test will be more sensitive and easier to use than current methods, and will ultimately help improve the survival of children with osteosarcoma.

The concept of resilience implies an ability to withstand stress after a significant crisis. While there are several theories of resilience, there is little consensus about how to define it or, more importantly, how to promote it. Cancer in children and adolescents can pose daunting challenges for patients as well as their families. This study explores a novel model of resilience among adolescents and parents of children with cancer. Promoting resilience during and after childhood cancer will promote more positive psychosocial outcomes and ultimately enable better family-level survivorship.

Based on progress to date, Dr. Friedman, was awarded a new grant in 2016 to fund an additional year of this Scholar award. Medulloblastoma, the most common malignant pediatric brain tumor, is a leading cause of cancer-related death. Current treatments are harmful to the developing brain. Brain tumor-initiating cells (BTIC), which give rise to all tumor cells like a queen bee, are likely responsible for cancer recurrence. Genetically-altered herpes simplex virus, which has been used safely and effectively in adult trials, targets and kills tumor cells and BTIC while sparing normal brain cells. This laboratory is studying the use of clinically-ready viruses in difficult-to-treat medulloblastomas, to provide the foundation for future pediatric trials using this cutting-edge therapy to benefit children with these deadly cancers.

A portion of the grant was generously supported by the Miracles for Michael Fund, a St. Baldrick's Hero Fund created in memory of Michael Orbany and honors his tremendous strength to never ever give up.

Based on progress to date, Dr. Lee, was awarded a new grant in 2016 to fund an additional year of this Scholar award. Immune cells can now be engineered to recognize and kill cancer cells, then administered to patients. Dr. Lee's project is one of the first to bring this promising new therapy to children with cancer. This research aims to discover how these cells work, how to better harness their potential and to determine which cell types are important for effective and persistent anti-tumor activity. Several clinical trials of this breakthrough therapy for children with cancer are scheduled to open at this institution and others in the next few years, and this work will increase the chance that these trials will be effective against childhood cancer. Awarded at the National Cancer Institute, National Institutes of Health and transferred to University of Virginia.

A portion of the grant was generously supported by the Hope from Harper Hero Fund created to honor Harper Wehneman who passed away from Wilms tumor when she was 9 years old. This fund continues her legacy of inspiring joy and bringing hope to kids fighting cancer by funding research in the area of stem cell transplant survival.

Based on progress to date, Dr. Wang, was awarded a new grant in 2016 to fund an additional year of this Scholar award. AML (acute myelogenous leukemia) is an often-fatal disease in children and adolescents. Part of the reason for limited success in curing AML is that current therapies don't attack the cancer stem cells that are responsible for maintaining the leukemia. Dr. Wang's research seeks to identify specific ways to target those hard-to-kill AML stem cells. To do this Dr. Wang is using the cutting-edge technologies of phosphoproteomics, which allow researchers to look at biologically vital pathways in cancer stem cells in a comprehensive, efficient, and novel manner. Awarded at Children's Hospital Boston and transferred to City of Hope.

A portion of this research was funded by P.A.L.S. Bermuda with funds raised through the St. Baldrick's Foundation.

Despite major improvement in outcomes for children and older adults with cancer over the past three decades, there has been little or no improvement in survival among adolescent and young adult (AYA) cancer patients (ages 15-39 years). The reasons for this disparity are not completely understood and likely include many factors, including differences in tumor biology, insurance coverage, clinical trial participation and adherence to treatment. This research aims to produce detailed information about the factors affecting AYA cancer incidence and survival that will help doctors target care and close this gap. The project will also produce detailed information for local cancer care service providers on where to target their efforts, and information that will help clinicians recruit AYA patients most in need of help to clinical trials to address their needs.

Dr. Phipps is studying what happens to children who were treated with bone marrow transplant for cancer many years ago. This is a very challenging treatment that can cause problems for survivors in a number of areas, including their thinking and learning ability, their physical health, and their ability to have children. He is learning how these children and young adults are faring relative to their healthy peers, to identify factors that lead to better or poorer outcomes so that researchers can develop treatments to prevent any negative effects.

Even though more and more children are being cured of cancer, the treatment can cause major life-long health problems for survivors. Unfortunately, most adult survivors don't seek appropriate medical care to monitor and care for these problems. This project is to study whether or not adult survivors referred to adult-focused follow-up care actually engage in such care and what might get in the way of doing so. The results of the study will help medical providers better prepare young adult survivors to engage in adult-focused follow-up care to assure that they stay as healthy as possible.

About 80% of children and adolescents diagnosed with cancer become long-term survivors. About half of them develop therapy-induced hearing loss that is cumulative and irreversible. Most at risk are patients with brain tumors, neuroblastomas, osteosarcomas, soft tissue sarcomas, retinoblastomas, hepatoblastomas, or germ cell tumors who need to be treated with cisplatin, combinations of cisplatin and carboplatin, radiation to the head and neck, or combinations of platins and radiation. Therapy-induced hearing loss adversely affects speech and language development, reading ability, communication, academic performance and psychosocial development. It frequently causes stress, social isolation, low self-esteem, and low overall quality of life. This project explores the use of moderate to high doses of dietary selenium as means to reduce or prevent cisplatin-induced hearing loss.

Based on progress to date, Dr. Davis was awarded a new grant in 2014 to fund an optional third year of this fellowship. Cancer affects teenagers and young adults more often than young children, but these in-between aged people have lower survival rates than yonger children. There aren't many doctors that specialize in treating these patients, but that is exactly what Dr. Davis is training to do. As part of this training, she is studying a bone cancer that occurs in teens. This same cancer affects pet dogs, too. She is testing drugs in a lab to see which ones kill the most tumor cells and then investigatimg why they work, in hopes that it will help both kids and dogs with this tumor live longer.

This grant helped provide staffing to support the adolescent and young adults (AYAs) Oncology program so that more kids can be treated on clinical trials, their best hope for a cure, at this institution.

This grant funds the expansion and sustainability of a comprehensive long-term follow-up program to monitor and treat secondary cancers and the many other health issues that young cancer patients face as they enter into adulthood.

There are currently over 350,000 childhood cancer survivors in the U.S., but treatments often result in persistent late-occurring health problems. One of the most devastating is congestive heart failure (CHF) resulting from treatment with a class of chemotherapy drugs called anthracyclines. It is estimated that 1 in 10 children treated with high-dose anthracyclines will develop CHF, with 1 in 2 dying within five years of diagnosis of CHF. Studies indicate that a low-dose blood pressure medication called carvedilol may help prevent the onset of CHF. This Consortium for Pediatric Intervention Research conducts a clinical trial with collaboration between five COG-member institutions. The project has the potential to not only improve overall cardiac function, but prevent the likelihood of developing CHF in survivors at highest risk. Funds administered by Beckman Research Institute of the City of Hope. Year two of this grant was generously funded by the Rally Foundation.

Adolescents with cancer experience many symptoms resulting from their disease and its treatment. Recognizing and managing these contributes to improved quality of life during treatment and on into survivorship. This study uses an approach that allows adolescents to identify clusters describing their symptom experience from their perspective. The purpose is to develop and test the use of a computer-based tool exploring symptom clusters among adolescents with cancer. The goal of these findings is to provide data to support use of the tool in a larger group of adolescents and to enhance communication between them and healthcare providers.